Using a ctDNA liquid biopsy assay for post-surgical serial monitoring and early detection of disease progression in advanced colorectal cancer patients
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F19%3AN0000131" target="_blank" >RIV/00064190:_____/19:N0000131 - isvavai.cz</a>
Výsledek na webu
<a href="http://dx.doi.org/10.1158/1538-7445.AM2019-405" target="_blank" >http://dx.doi.org/10.1158/1538-7445.AM2019-405</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1158/1538-7445.AM2019-405" target="_blank" >10.1158/1538-7445.AM2019-405</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Using a ctDNA liquid biopsy assay for post-surgical serial monitoring and early detection of disease progression in advanced colorectal cancer patients
Popis výsledku v původním jazyce
Introduction: ctDNA liquid biopsy has been recognized as a useful approach to monitor effect of ongoing cancer treatment. The ctDNA dynamics is reflecting the overall tumor burden. Here we present a utility of a simple ctDNA assay for longitudinal monitoring of patients with advanced stages of colorectal cancer in conjunction with surgical treatment. Patients and Methods: In a prospective setting the disease course of a total of 121 patients in Stage III and IV of colorectal cancer was monitored by ctDNA. A panel of somatic mutations was initially screened in primary and/or metastatic tissue. The found mutations were then traced in ctDNA from plasma acquired before surgery and during the subsequent days and months. In a subgroup of rectal cancers ctDNA was also analyzed prior and during the neoadjuvant chemoradiotherapy. The ctDNA levels were then correlated to the clinical parameters such as surgical radicality, disease relapse or response to anticancer therapy.
Název v anglickém jazyce
Using a ctDNA liquid biopsy assay for post-surgical serial monitoring and early detection of disease progression in advanced colorectal cancer patients
Popis výsledku anglicky
Introduction: ctDNA liquid biopsy has been recognized as a useful approach to monitor effect of ongoing cancer treatment. The ctDNA dynamics is reflecting the overall tumor burden. Here we present a utility of a simple ctDNA assay for longitudinal monitoring of patients with advanced stages of colorectal cancer in conjunction with surgical treatment. Patients and Methods: In a prospective setting the disease course of a total of 121 patients in Stage III and IV of colorectal cancer was monitored by ctDNA. A panel of somatic mutations was initially screened in primary and/or metastatic tissue. The found mutations were then traced in ctDNA from plasma acquired before surgery and during the subsequent days and months. In a subgroup of rectal cancers ctDNA was also analyzed prior and during the neoadjuvant chemoradiotherapy. The ctDNA levels were then correlated to the clinical parameters such as surgical radicality, disease relapse or response to anticancer therapy.
Klasifikace
Druh
D - Stať ve sborníku
CEP obor
—
OECD FORD obor
30204 - Oncology
Návaznosti výsledku
Projekt
<a href="/cs/project/NV15-27939A" target="_blank" >NV15-27939A: Přínos nové technologie „liquid biopsy“ pro monitoraci komplexní léčby kolorektálního karcinomu ve 3.- 4. stádiu onemocnění</a><br>
Návaznosti
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Ostatní
Rok uplatnění
2019
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název statě ve sborníku
Proceedings: AACR Annual Meeting 2019
ISBN
—
ISSN
0008-5472
e-ISSN
—
Počet stran výsledku
2
Strana od-do
Abstract 405
Název nakladatele
American Association for Cancer Research
Místo vydání
Atlanta
Místo konání akce
Atlanta
Datum konání akce
29. 3. 2019
Typ akce podle státní příslušnosti
WRD - Celosvětová akce
Kód UT WoS článku
—